(November 17, 2016, 5:53 PM EST) -- WASHINGTON, D.C. — Amgen Inc. and Amgen Manufacturing Ltd. (collectively, Amgen) argue in a Nov. 8 opposition brief that the U.S. Supreme Court should decline to review whether the Federal Circuit...
Amgen Opposes Review Of Commercial Marketing Notice To Product Sponsor
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login